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Interleukin 21 controls tumour growth and tumour
immunosurveillance in colitis-associated
tumorigenesis in mice
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ABSTRACT
Background and aims Colitis-associated tumorigenesis
is a balance between proliferation of tumour cells and
tumour immunosurveillance. The role of T-helper-cell-
derived cytokines in tumour growth is not fully
understood. In this study the authors investigated the
influence of interleukin (IL) 21 on intestinal
tumorigenesis.
Methods Chronic colitis was induced in IL-21/ and
littermate control wild-type mice with three cycles of
1.5% dextran sulphate sodium (DSS) over 7 days
followed by 7 days of drinking water. Mice received an
azoxymethane injection on day 0 of DSS-colitis to induce
tumorigenesis. Immunohistochemistry was performed on
inflamed and tumour-bearing areas of colons. Cytokine
expression of isolated colonic CD4 T cells was
determined by ELISA. Cytotoxic capacity of isolated
colonic CD8 T cells targeting tumour cells was evaluated
by flow cytometry and quantitative cytotoxicity assay.
Apoptosis of tumour cells was determined by TUNEL
assay of colonic sections.
Results Increasing expression of IL-21 was observed in
chronic colitis, which showed functional importance,
since IL-21 deficiency prevented chronic DSS-colitis
development. Further, in the absence of IL-21,
significantly fewer tumour nodules were detected,
despite a similar extent of intestinal inflammation. In
wild-type mice, 8.661.9 tumour nodules were found
compared with 1.061.2 in IL-21-deficient mice. In
tumour-bearing IL-21-deficient mice, intestinal
inflammation was restored and partly dependent on
interferon (IFN)-g, whereas the inflammation in wild-type
mice showed high IL-17A concentrations. In these rare
tumours in IL-21-deficient mice, tumour cell proliferation
(Ki-67) was decreased, while cell apoptosis was
increased, compared with wild-type mice. Increased
IFNg expression in tumour-bearing IL-21-deficient mice
led to increased tumour immunosurveillance mediated by
cytotoxic CD8CD103 T cells targeting E-cadherin+
colonic tumour cells and therefore limited tumour
growth.
Conclusion These results indicate that IL-21
orchestrates colitis-associated tumorigenesis, leading to
the hypothesis that high IFNg and low IL-17A expression
reduces tumour cell proliferation and increases tumour
immunosurveillance.
INTRODUCTION
Long-lasting inﬂammatory bowel disease is accom-
panied by an increased risk of colorectal adenocar-
cinoma development.1e4 Based on information
obtained from a variety of animal studies, it is
obvious that the presence of chronic inﬂammation
provides a milieu that favours tumour cell prolifer-
ation. For instance, molecules that mediate or regu-
late proinﬂammatory innate immune signalling have
been shown to inﬂuence the local milieu during
colitis-associated tumour growth.5e14 One of the
key features of cells of the innate immune system
during colonic tumour development is the produc-
tion of cytokines that induce antigen-driven differ-
entiation of the adaptive immune system.15
Therefore the role of adaptive immunity in estab-
lishing the local cytokine milieu during colitis-
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Significance of this study
What is already known about this subject?
< Chronic inflammation supports tumour growth.
< Tumour immunosurveillance can suppress
tumour growth.
< IL-21 can tip the balance between Th1 and Th17
differentiation.
< IL-21-deficient mice are protected from acute
intestinal inflammation.
What are the new findings?
< Intestinal tumour growth is reduced in the
absence of IL-21 and this reduction is not due
to ameliorated colitis.
< IL-21 is necessary to establish a tumour-
supportive colonic micro milieu.
< In the absence of IL-21, colonic inflammation is
driven by IFNg which leads to increased tumour
immunosurveillance.
< Tumour immunosurveillance is mediated by
CD8CD103 T cells targeting E cadherin+ trans-
formed epithelial cells.
How might it impact on clinical practice in the
foreseeable future?
< Inflammatory infiltrates can be detected in
a broad variety of tumours and their metastases.
Understanding the inflammatory infiltrate char-
acterising the tumour microenvironment and its
effect on tumour immunosurveillance will help to
establish new treatment options in cancer
treatment. Targeting IL-21 is a potential target
for limiting tumour growth and increasing
tumour immunosurveillance in colitis-associated
tumour growth.
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associated tumour growth is not yet understood. In particular,
adaptive Th1 and Th17 cells have the capacity to inﬂuence the
local cytokine milieu in the colon, polarising the immune response
towards intestinal inﬂammation. IL-21 is a particularly interesting
cytokine to study in this respect because it affects the develop-
ment of naïve Tcells into Th1 or Th17 cells.15 Themain sources of
IL-21 under autoinﬂammatory conditions are NK cells and acti-
vated CD4 Tcells.
In the present study, we aimed to examine the importance of
IL-21 in the development of chronic intestinal inﬂammation as it
relates to tumour growth. Further analyses focused on the
importance of tumour immunosurveillance mediated by cyto-
toxic CD8 T cells and its dependency on the local cytokine
milieu, which is inﬂuenced by the presence of IL-21 during
chronic intestinal inﬂammation with tumour growth. Results
from our study suggest that IL-21 is essential for the generation
of a tumour-proliferative cytokine milieu and for the control of
tumour immunosurveillance, both of which are key aspects of
colitis-associated tumour growth.
METHODS
Mice
Speciﬁc pathogen-free IL-21/ (B6;129S5) and littermate control
wild-type mice (2e4 months old) were housed in the animal
facility at the University of Regensburg. IL-21/ B6;129S5 mice
were initially obtained from the Mutant Mouse Regional
Resource Center (University of California Davis). For transfer
colitis, IL-21/ mice and littermate controls were back-crossed
on to a C57BL/6 background. Animal use was approved by the
laboratory animal care guidelines of theUniversity of Regensburg.
Induction of colitis
Chronic dextran sulphate sodium (DSS)-colitis was induced by
three cycles of 1.5% DSS in drinking water for 1 week followed
by normal drinking water for 1 week. Colitis-associated tumor-
igenesis was induced by intraperitoneal injection of a single dose
of azoxymethane (AOM) (10 mg/kg; Sigma Aldrich, St Louis,
Missouri, USA) on day 0, followed by chronic DSS-colitis.
Cell isolation and cytokine measurement
Lamina propria mononuclear cells were isolated from colonic
tissues as previously described.16 17 CD4 cells were isolated by
magnetic bead sorting (Miltenyi Biotec, Bergisch Gladbach,
Germany) and cultured for 48 h under stimulation with plate-
bound antibody to CD3 (10 mg/ml) and soluble antibody to
CD28 (1 mg/ml) (BD Biosciences, San Jose, California, USA).
Cytokine concentrations were measured using ELISA kits,
according to the manufacturer ’s instructions (BD Biosciences,
San Jose, California, USA).
Immunohistochemistry
Sections were incubated with antibodies to Ki-67 (Dako,
Hamburg, Germany), Foxp3 (Abcam, Cambridge, UK), b-catenin
(Cell Signaling Technology, Danvers, Massachusetts, USA) and
E-cadherin (Cell Signaling Technology). TUNEL assay was
performed according to the manufacturer ’s (Roche, Mannheim,
Germany) protocol. For calculation of the extent of inﬂamma-
tion, H&E sections were examined by investigators blinded to
the experimental protocol and according to a previously
published scoring system.18
CTL assays
CTL assays (cytotoxic T-lymphocyte assay) were performed using
CD8 cells isolated from DSS-treated, tumour-bearing mice.
Isolated CD8 cells were co-incubated in vitro with either CT-26
cells or E-cadherin-transfected CT-26 cells (53104 cells). Cytolytic
activity was determined by CellTiter-Glo Luminescent Cell
Viability Assay (Promega, Madison, Wisconsin, USA). Performing
a cytotoxicity assay with CD8 T cells obtained from B6;129S5
mice using allogeneic CT-26 cells resulted in a higher baseline level;
however, the relative increase in cytotoxicity between treatment
groups, compared with baseline levels, remained quite stable.
Statistical analysis
For calculation of differences in histology score and proliferation
index, a KruskaleWallis test with Dunn’s multiple comparison
test was used. For calculation of differences in the number of
tumour nodules and cytokine concentrations, a two-way anal-
ysis of variance test with Bonferroni post-test was used. A value
of p<0.05 was considered signiﬁcant.
RESULTS
IL-21 is upregulated in chronic intestinal inflammation
IL-21 is a key effector cytokine for acute experimental colitis.19 In
our studies, we began to dissect the importance of IL-21 in the
development of chronic intestinal inﬂammation and the related
long-term complication of colonic tumour growth by ﬁrst inves-
tigating chronic colitis without tumour growth. We found that
increasing amounts of IL-21 are detectable during the course of
chronic colitis induced by DSS or 2, 4, 6-trinitrobenzenesulfonic
acid (TNBS) in wild-type mice, or by transfer of naïve T cells to
Rag1/ mice (online supplementary ﬁgure S1A,B).
IL-21-deficient mice are protected against the development of
chronic DSS-colitis
After DSS administration to wild-type mice, we observed severe
chronic colitis. However, IL-21-deﬁcient mice were protected from
this type of inﬂammation (ﬁgure 1A). Further, on day 42 we found
a dramatic loss of colonic crypts and a signiﬁcant reduction in
goblet cell numbers in wild-type mice. In contrast, the morphology
and architecture of colonic tissue obtained from IL-21-deﬁcient
mice treated with DSS remained mostly intact (ﬁgure 1B).
Notably, general cellular proliferation measured by Ki-67 staining
within intestinal tissue was signiﬁcantly decreased after DSS
treatment in IL-21-deﬁcient mice (online supplementary ﬁgure S2).
We further determined the expression levels of IL-17A and
IFNg on day 42 of chronic DSS-colitis induction. As shown in
ﬁgure 1C, isolated CD4 cells from mesenteric lymph nodes of IL-
21-deﬁcient mice produced signiﬁcantly less IL-17A and IFNg
than wild-type animals. Similar ﬁndings were obtained in the
cell transfer colitis model (online supplementary ﬁgure S3). A
potential role for IL-17A and low IFNg in an ‘IL-21-mediated’
tumour-promoting effect was then considered.
Indeed, previous reports suggest that IL-21 can modulate the
balance between Th17 cells and Foxp3+ Treg.20 We did not
observe any difference in the distribution of Foxp3+ Treg on day
42 after DSS treatment initiation in wild-type versus IL-
21-deﬁcient mice (online supplementary ﬁgure S4). This obser-
vation is in contrast with data obtained from mice with acute
DSS-colitis (online supplementary ﬁgure S5). Similar changes
were obtained via ﬂow cytometric analysis examining for CD4
Foxp3+ Treg isolated cells from the colon of wild-type and IL-
21-deﬁcient mice (data not shown).
Tumour growth during chronic DSS-colitis is dependent on the
presence of IL-21
We next combined chronic DSS-colitis with an initial intraper-
itoneal administration of the carcinogenic substance AOM. We
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found that wild-type mice displayed an average of eight tumour
nodules per colon on day 42, whereas there was only about one
in IL-21-deﬁcient mice (ﬁgure 2A).
H&E staining revealed that tumour nodules consisted mostly of
adenoma tissue, with low- to high-grade intraepithelial neoplasia
(ﬁgure 2B). Although the morphology of tumours from wild-type
and IL-21-deﬁcient mice was similar, the diameter of tumours from
IL-21-deﬁcient mice was 30e40% less. Consistent with this
observation, Ki-67 staining revealed a lower cell proliferation rate in
tumours derived from IL-21-deﬁcient mice (ﬁgure 2C). Examination
of transformed epithelial cells revealed an intracellular and nuclear
expression pattern of b-catenin in tumour cells in wild-type and IL-
21-deﬁcient mice, whereas non-tumorous epithelial cells showed
weak cell membrane staining of b-catenin (ﬁgure 2D). To rule out
the possibility that the decreased tumour burden in IL-21-deﬁcient
mice on day 42 was because these mice exhibit less severe colitis
during the early course of the disease, we observed wild-type and
IL-21-deﬁcient mice until day 84 after the initiation of the model.
As shown in ﬁgure 2E, wild-type mice had developed an average of
nine tumour nodules on day 42 and an average of almost 20
tumour nodules on day 84. IL-21-deﬁcient mice showed hardly any
tumour burden on either day 42 or day 84, despite the fact that
chronic colitis lasted until day 84. This experiment demonstrates
that, despite chronic colitis, starting between days 21 and 28, IL-
21-deﬁcient mice are largely protected from tumorigenesis.
Tumour growth restores inflammatory signs in IL-21-deficient
mice
Initially, we hypothesised that the reason for reduced tumour
formation in IL-21-deﬁcient mice would be reduced intestinal
inﬂammation. However, we found that the inﬂammation was
similar in wild-type and IL-21-deﬁcient mice on day 42 of
chronic DSS-colitis and AOM-induced tumour growth (ﬁgure
3A). It is worth noting that this restoration of intestinal
inﬂammation in IL-21-deﬁcient mice with AOM-induced
tumour growth was observed despite the use of a similar
approach for inducing the underlying chronic DSS-colitis (as
shown in ﬁgure 2), with the exception of not administering
AOM.
High IFNg expression in IL-21-deficient mice with intestinal
tumorigenesis
To further elucidate the inﬂammatory milieu associated with
intestinal tumour growth with regard to IL-21 deﬁciency, we
determined cytokine expression in inﬂamed areas of colitis and
tumour-bearing areas. Figure 3b shows a signiﬁcant decrease in
IL-17A production on day 42 in tumour-bearing IL-21-deﬁcient
mice compared with results in wild-type mice. However, IFNg
expression during chronic DSS-colitis with AOM-induced
tumour growth showed the opposite: in the presence of
tumours, an increase in IFNg production was detected in IL-
21-deﬁcient mice. These results suggest that the presence of
AOM-induced tumours resulted in a change in the local cytokine
milieu, and that a high concentration of IFNg expression in IL-
21-deﬁcient mice does not support tumour growth to the extent
seen in an IL-17A-dominated micro milieu in wild-type mice.
We further investigated the expression pattern of IL-6 and IL-
22, cytokines that are both potentially proproliferative and
antiapoptotic for intestinal epithelial cells. There were no
changes in IL-6 or IL-22 production on day 42 (ﬁgure 3B). In
Figure 1 Interleukin (IL)-21-deficient
mice are protected from chronic
dextran sulphate sodium (DSS)-colitis.
(A) H&E staining of representative colon
sections and histology score on day 42
of chronic DSS-colitis. Data shown are
mean values 6 SEM and derived from
at least 10 mice per group. Individual
points represent one mouse. *p#0.05.
(B) Alcian blue/periodic acid Schiff
(PAS) staining of representative colon
sections on day 42 of chronic DSS-
colitis. (C) IL-17A and interferon (IFN)-g
expression on day 42 of chronic DSS-
colitis. CD4 cells were extracted from
mesenteric lymph nodes and stimulated
for 48 h. Cytokine concentrations were
determined in culture supernatants by
ELISA. Data shown are mean values 6
SEM, derived from at least five mice per
group. *p#0.05. KO, knock-out; WT,
wild-type.
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addition, we determined the distribution of follicular helper CD4
T cells in mesenteric lymph nodes on day 35 of chronic DSS-
colitis with AOM-induced tumour formation. We found no
changes in the number of these cells (as determined by ﬂow
cytometry for CD4CD44highPD1+CXCR5high cells) in wild-type
or IL-21-deﬁcient mice (online supplementary ﬁgure S6). Further,
we did not observe any differences in architecture of spleens and
mesenteric lymph nodes.
As tumour-bearing IL-21-deﬁcient mice showed an unex-
pected change in cytokine production on day 42, we determined
the expression of IL-17A and IFNg during the early phase of
chronic DSS-colitis with AOM-induced tumour transformation
of colonic epithelial cells. IL-17A was only detectable at low
concentrations on day 7 and day 21 in IL-21-deﬁcient mice.
However, IFNg showed a signiﬁcant increase on day 21 in IL-
21-deﬁcient mice with tumour growth (ﬁgure 3C). These data
indicate that the cytokine switch occurs during the transition
phase from acute to chronic intestinal inﬂammation after
AOM-induced tumour transformation.
To investigate whether changes in histological architecture of
colons from wild-type mice or IL-21-deﬁcient mice during
chronic DSS-colitis with AOM-induced tumorigenesis occur
during the transition phase from acute to chronic colitis, we
carried out a time course experiment to assess histological
scoring on a weekly interval. We found that the onset of
increased colitis in IL-21-deﬁcient mice was on day 21 and
further increased until day 28 (ﬁgure 3D). Therefore the extent
of inﬂammation changes in accordance with the increase in
IFNg production in IL-21-deﬁcient mice during chronic
DSS-colitis with AOM-induced tumorigenesis.
An adaptive immune response characterised by the presence
of IL-17A or IFNg is preceded by the production of IL-23 or IL-
12, respectively. Therefore we determined the production of
these two cytokines by colonic CD11b cells during the transi-
tion phase of chronic DSS-colitis with AOM-induced tumori-
genesis. We found that IL-23 was upregulated in wild-type mice,
whereas IL-12p70 was greatly increased in IL-21-deﬁcient mice
(ﬁgure 3E). We hypothesised that this change in cytokine
production may be based on an epithelial-derived factor that is
stimulating antigen-presenting cells to produce either IL-23 or
IL-12. We harvested colonic epithelial cells on day 21 from either
wild-type or IL-21-deﬁcient mice and incubated naive CD11b
cells with lysates of these epithelial cells. Interestingly, we found
that lysates obtained from IL-21-deﬁcient mice were able to
Figure 2 Tumour number is decreased in the absence of interleukin (IL0-21. (A) Number of tumour nodules on day 42 of chronic dextran sulphate
sodium (DSS)-colitis with azoxymethane (AOM)-induced tumour growth. Data shown are mean values 6 SEM, derived from at least 10 mice per
group. Individual points represent one mouse. *p#0.05. (B) H&E staining in representative tumour areas of colon sections and tumour size on day 42
of chronic DSS-colitis with AOM-induced tumour growth. Measurements of tumour nodules refer to diameter and were made using a digitally obtained
image of the whole tissue section. Evaluation was performed using the Mirax Viewer software (Carl Zeiss AG, Germany). (C) Ki-67 staining of
representative tumour areas of colon sections and proliferation score on day 42 of chronic DSS-colitis with AOM-induced tumour growth. Data shown
are mean values 6 SEM, derived from at least 10 mice per group. Individual points represent one mouse. *p#0.05. (D) b-Catenin staining of
representative tumour areas of colon sections on day 42 of chronic DSS-colitis with AOM-induced tumour growth. (E) Number of tumour nodules on
day 42 and 84 of chronic DSS-colitis with AOM-induced tumour growth. Data shown are mean values6 SEM, derived from at least 10 mice per group.
Individual points represent one mouse. *p#0.05. HPF, high power field; KO, knock-out; WT, wild-type.
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induce IL-12p70 production from either wild-type or IL-
21-deﬁcient CD11b cells (online supplementary ﬁgure S7A). We
also generated conditioned media from complete colon tissue,
isolated intestinal epithelial cells, lamina propria CD3 T cells,
and F4/80+ macrophages obtained from wild-type and IL-
21-deﬁcient mice on day 21 of DSS-colitis with AOM-induced
tumorigenesis. Naive CD11b cells were then cultured in condi-
tioned medium, and IL-12p70 production was determined. We
found that only conditioned medium from colon tissue or
isolated intestinal epithelial cells from IL-21-deﬁcient mice were
able to induce an increase in IL-12p70 production (online
supplementary ﬁgure S7B). These changes in inﬂammatory
response are also reﬂected in weight curves of wild-type and IL-
21-deﬁcient mice during chronic DSS-colitis with or without
AOM-induced tumorigenesis (online supplementary ﬁgure S8).
This set of data strengthens the hypothesis that epithelial-
derived factors are at least partly responsible for polarisation of
the adaptive immune response during chronic DSS-colitis with
AOM-induced tumorigenesis.
IFNg induces inflammation and tumour control in IL-21-deficient
mice
Further analysis was performed to determine the role of IFNg
during chronic intestinal inﬂammation and tumour growth. For
this purpose, DSS-colitis with initial AOM injection was estab-
lished and combined with IFNg antibody administration twice
weekly starting on day 14. We found that inhibition of IFNg did
not affect chronic colitis in wild-type mice; however, it signiﬁcantly
reduced colitis in IL-21-deﬁcient mice (ﬁgure 4A). Furthermore,
antibody interference with IFNg resulted in an increase in tumour
number in IL-21-deﬁcient mice compared with IL-21-deﬁcient mice
receiving control IgG (ﬁgure 4B). Our results indicate that IFNg at
least partly mediates intestinal inﬂammation in IL-21-deﬁcient
mice with chronic DSS-colitis and AOM-induced tumour growth.
Figure 3 Restored inflammation in interleukin (IL)-21-deficient mice with chronic dextran sulphate sodium (DSS)-colitis and tumorigenesis. (A) H&E
staining of representative inflammatory areas of colon sections and histology score on day 42 of chronic DSS-colitis with azoxymethane (AOM)-
induced tumour growth. Data shown are mean values 6 SEM, derived from at least 10 mice per group. Individual points represent one mouse.
*p#0.05. (B) IL-17A, interferon (IFN)-g, IL-6 and IL-22 expression on day 42 of chronic DSS-colitis with AOM-induced tumour growth. CD4 or CD11b
cells were extracted from the lamina propria of inflamed and tumour-bearing areas, and then stimulated for 48 h. Cytokine concentrations were
determined in culture supernatants by ELISA. Data shown are mean values6 SEM, derived from at least five mice per group. *p#0.05. (C) IL-17A and
IFNg expression on day 7 and day 21 of chronic DSS-colitis with AOM-induced tumour growth. CD4 cells were extracted from the lamina propria from
inflamed and tumour-bearing areas and stimulated for 48 h. Cytokine concentrations were determined in culture supernatants by ELISA. Data shown
are mean values6 SEM, derived from at least five mice per group. *p#0.05. (D) Histology score on days 14, 21, 28 and 35 of chronic DSS-colitis with
AOM-induced tumour growth. Data shown are mean values 6 SEM, derived from at least seven mice per group. Individual points represent one
mouse. (E) IL-23 and IL-12p70 expression on day 7 and day 21 of chronic DSS-colitis with AOM-induced tumour growth. CD11b cells were extracted
from the lamina propria and stimulated for 48 h. Cytokine concentrations were determined in culture supernatants by ELISA. Data shown are mean
values 6 SEM, derived from at least five mice per group. *p#0.05. KO, knock-out; WT, wild-type.
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CD8 T cells control tumour growth
Previous work has shown that IFNg is able to promote an
antitumour response, which can be mediated by CD8 cytotoxic
Tcells. To test for a potential role of CD8 Tcells in this model, we
administered antibody to CD8 weekly starting on day 14 of
chronic DSS-colitis with AOM-induced tumour growth.
Although CD8 antibody treatment reduced the number of
circulating CD8 T cells by 85% (data not shown), this depletion
did not inﬂuence the level of inﬂammation of chronic DSS-colitis
with AOM-induced tumour growth (ﬁgure 5A). The number of
tumour nodules per mouse and the diameter increased signiﬁ-
cantly with CD8 Tcell depletion in wild-type and IL-21-deﬁcient
mice (ﬁgure 5B and C). To determine if NKT cells or NK cells
might be exerting cytotoxic effects in terms of tumour immu-
nosurveillance during chronic DSS-colitis with AOM-induced
tumour growth, we depleted these cell types by administering
antibody against either CD1 or asialo GM1 (starting on day 14),
respectively. As shown in online supplementary ﬁgure S9, neither
depletion of NKT cells nor depletion of NK cells resulted in
a change in tumour burden in wild-type and IL-21-deﬁcient mice.
Cytotoxicity against tumour epithelial cells increases in IL-21-
deficient mice
Previous studies show that cytotoxic CD8 T cells speciﬁc for
tumour cells limit tumour growth (immunosurveillance), as
CD8 T cells bearing CD103 (aEb7) can bind E-cadherin
on tumour cells.21e23 Tumour cells from wild-type and IL-
21-deﬁcient mice have a similar E-cadherin expression pattern
during chronic DSS-colitis with AOM-induced tumour growth
(ﬁgure 6A). Therefore the potential target cell for cytotoxic CD8
T cells was available in either wild-type or IL-21-deﬁcient mice.
However, as shown in ﬁgure 6B, wild-type mice with AOM-
induced tumour growth had fewer CD8CD103 Tcells on day 28
than similarly treated IL-21-deﬁcient mice.
The cytotoxic potential of CD8 T cells was demonstrated by
the extent of granzyme B and perforin expression on day 28.24 25
This evaluation time point was chosen in order to investigate
the cytotoxic potential of CD8 T cells at the time of early
tumour immunoediting. CD8 T cells from IL-21-deﬁcient mice
showed a signiﬁcant increase in granzyme B and a slight increase
in perforin expression. Cytotoxic effects of CD8 T cells isolated
from colon tumours against (allogeneic) CT-26 colon tumour
cells (not expressing E-cadherin) and CT-26 cells transfected
with an E-cadherin-expressing plasmid were tested. CD8 T cells
from wild-type mice exhibited only minimal cytotoxicity
against untransfected CT-26 cells, although they did exhibit
substantial cytotoxicity against transfected E-cadherin-
expressing CT-26 cells (ﬁgure 6C). CD8 Tcells isolated from IL-
21-deﬁcient mice showed a relatively enhanced cytotoxic effect
against E-cadherin-expressing CT-26 cells. These results are
consistent with our ﬁnding that tumours from IL-21-deﬁcient,
versus wild-type mice, showed a signiﬁcant increase in apoptotic
cells as determined by TUNEL staining (ﬁgure 6D). Finally, we
examined the dependence of this cytotoxic effect on IFNg and
evaluated the presence of cytotoxic CD8CD103 T cells in the
colon after IFNg antibody treatment. The inhibition of IFNg
resulted in a signiﬁcant reduction of CD8CD103 T cells in the
colon of IL-21-deﬁcient mice (ﬁgure 6E). Therefore we could
demonstrate that the presence of cytotoxic CD8CD103 Tcells in
IL-21-deﬁcient mice was dependent on IFNg. Together, these
data show that, while cytotoxic CD8CD103 T cells are poten-
tially capable of exerting immunosurveillance functions against
tumour cells, this function is probably controlled by the
cytokine milieu in the colon.
Figure 4 Interferon (INF)g regulates
inflammation and tumour growth in the
absence of interleukin (IL)-21. (A) H&E
staining of representative colon
sections of inflamed areas and histology
score on day 42 of chronic dextran
sulphate sodium (DSS)-colitis with
tumour growth after inhibition of IFNg.
Inhibition of IFNg started on day 14.
Data shown are mean values 6 SEM,
derived from at least 10 mice per group.
Individual points represent one mouse.
*p#0.05. (B) Number of tumour
nodules on day 42 of chronic DSS-
colitis with azoxymethane-induced
tumour growth after inhibition of IFNg.
Inhibition of IFNg was started on day
14. Data shown are mean values 6
SEM, derived from at least 10 mice per
group. Individual points represent one
mouse. *p#0.05. KO, knock-out; WT,
wild-type.
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DISCUSSION
The aetiology of inﬂammatory bowel disease, consisting
primarily of Crohn’s disease and ulcerative colitis, is not fully
understood.26e28 One long-term consequence of an altered
immune homoeostasis at the mucosal surface is development of
colorectal cancer. In this article, we demonstrate that IL-21 is an
important factor in tumour growth and immunosurveillance
during colitis-associated tumorigenesis. In this regard, we show
that IL-21 is necessary for the establishment of a tumour-
supportive micro milieu in the colon, which is characterised by
the presence of the cytokine IL-17A and limited tumour
immunosurveillance through reduced concentrations and func-
tional capacity of cytotoxic CD8CD103 T cells.
Although an important effect of IL-21 on the development of
chronic intestinal inﬂammation was expected, the situation
changed when tumour growth was accompanied by robust
intestinal inﬂammation even in the absence of IL-21; this
inﬂammation was partly mediated through IFNg produced by
CD4 Tcells. It was obvious that the intestinal inﬂammation and
tumour growth were able to interact in both directions. This
important link between inﬂammation and cancer has been
known for centuries.29 30 The inﬂammation orchestrates the
microenvironment around tumours, and the tissue distribution
of T cell subsets in human cancers clearly shows that a broad
variety of solid tumours are associated with an increase in
tumour microenvironmental Th17 cells.31 32 In our study,
tumour growth in wild-type mice was associated with high
production of IL-17A by inﬁltrating CD4 T cells and a reduced
concentration of IFNg, mimicking the cytokine pattern
observed in a variety of human solid tumours.33e36 Importantly,
our results indicate that the balance between these two polar-
ised T cell subsets is tipped by IL-21.
It is widely accepted that tumour cell proliferation can be
mediated through Tcells after stimulation with tumour antigen
that is presented by tumour-associated macrophage cells,
a cellular interaction known to induce IL-17 expression.33 Our
results indicate that IL-21 has a major role in the generation of
a proliferative, IL-17A-based, tumour microenvironment. We
have demonstrated that, in the absence of IL-21, the inﬂam-
matory response is characterised by high IFNg concentration,
not by high IL-17A concentration. Therefore one can assume
that the reduction in tumour number in the absence of IL-21 is
not based on the existence of inﬂammation, but rather on the
speciﬁc characteristics of the tumour microenvironment. This
change in tumour microenvironment is in concordance with
ﬁndings of previous reports in which IL-21 could inhibit IFNg
expression when IL-21 was present at the time of naïve CD4 T
cell priming under Th1 conditions.37 In addition to our ﬁndings
in mice, it has been shown that human biopsy specimens
obtained from patients with Crohn’s disease produce less IFNg
when IL-21 is blocked in an ex vivo culture.38 This set of data
published by Monteleone et al does not necessarily contradict
our ﬁndings, as we have also found that IFNg expression is very
low in IL-21-deﬁcient mice in the absence of tumours. Further-
more, Sarra et al demonstrated that, in the human gut, IL-21 is
mainly produced by CD4 T cells co-expressing IFNg.39 There-
fore, a likely explanation for reduced IFNg production by ex vivo
culture of biopsy specimens from patients with Crohn’s disease
is that the inhibition of IL-21 concomitantly blocks the
production of IFNg from the same cell.
It is well accepted that IL-21 plays a pathogenic role in
intestinal inﬂammation. However, this effect has not been seen
in a situation when tumour induction was incited by AOM. In
our work, we show that epithelial cell lysates and conditioned
Figure 5 CD8 T cells control tumour
growth. (A) H&E staining of
representative colon sections of
inflamed area and histology score on
day 42 of chronic dextran sulphate
sodium (DSS)-colitis with tumour
growth, after deletion of CD8 T cells.
CD8 T cell deletion was started on day
14. Data shown are mean values 6
SEM, derived from at least 10 mice per
group. Individual points represent one
mouse. *p#0.05. (B) Number of
tumour nodules on day 42 of chronic
DSS-colitis with azoxymethane (AOM)-
induced tumour growth, after deletion
of CD8 T cells. CD8 T cell deletion was
started on day 14. Data shown are
mean values 6 SEM, derived from at
least 10 mice per group. Individual
points represent one mouse. *p#0.05.
(C) Diameter of tumour nodules on day
42 of chronic DSS-colitis with AOM-
induced tumours after deletion of CD8 T
cells. CD8 T cell deletion was started on
day 14. Measurements of tumour
nodules refer to diameter and were
made using a digitally obtained image
of the whole tissue section. Evaluation
was performed using Mirax Viewer
software (Carl Zeiss AG, Germany). KO,
knock-out; WT, wild-type.
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media obtained from isolated epithelial cells of IL-21-deﬁcient
mice after AOM administration are able to induce a strong Th1
response that is in turn mediating the colitis, albeit with
a different cytokine pattern of inﬂuence. We have not yet
elucidated the actual factor released by intestinal epithelial cells
to induce a Th1-polarised colonic microenvironment. One
potential candidate for the induction of IL-12 production by
CD11b cells with consecutive IFNg expression is IL-18, which
was initially described as IFNg-inducing factor. IL-18 is upre-
gulated in the intestinal mucosa of patients with inﬂammatory
bowel disease, and blockade of IL-18 reduces the extent of
intestinal inﬂammation induced by DSS.40 In accordance with
the hypothesis that IL-18 might initiate a tumour-suppressive
Th1-based microenvironment, recent work from Salcedo et al
has shown that IL-18-deﬁcient mice have a much higher tumour
burden than wild-type mice during chronic DSS-colitis with
AOM-induced tumour formation.7 However, additional research
is necessary to test this hypothesis.
In addition, inﬂammatory cells in the tumour microenviron-
ment may have an important role in initiating and maintaining
protective antitumour immunity by tumour immunoediting.
One such effect investigated in our study relates to the immu-
nosurveillance of AOM-induced tumours mediated by cytotoxic
cells. After excluding NK cells and NKT cells as possible cyto-
toxic effector cells, we could demonstrate that the capacity of
CD8 T cells to be immunosurveillant is inherent in their ability
to kill epithelial cell tumour lines bearing E-cadherin (a CD103
ligand) ex vivo. Notably, the presence of CD8CD103 cytotoxic T
cells was greatly increased in the absence of IL-21 and dependent
on IFNg. These results are consistent with facilitated binding of
antitumour CD8CD103 Tcells to E-cadherin-expressing tumour
cells.41 Moreover, under these conditions, killing is presumably
mediated by a granzyme B-dependent effect of CD8 cytotoxic T
cells, as this potent cytotoxic molecule was highly upregulated
in CD8 Tcells of IL-21-deﬁcient mice. The reason why a tumour
microenvironment with a high expression level of IFNg
promotes an antitumour response probably lies in the capacity
of IFNg to facilitate maturation of CD8 cytotoxic T cells.42 In
fact, IFNg has been associated with antitumour immunity and
its dependence on the adaptive immune system in a variety of
different tumour entities.43 44 Previous in vitro experiments have
shown that IL-21 can inﬂuence the proliferation of CD8 Tcells,
whereas the cytotoxic function is not compromised.45 46 In
addition, Hinrichs et al showed that antigen-induced acquisition
of effector CD8 T cell phenotype and function is suppressed by
the presence of IL-21.47 These facts are in accordance with data
presented in this article, since the number of CD8 T cells
remained stable regardless of the presence of IL-21. However, the
Figure 6 Tumour immunosurveillance increases in the absence of interleukin (IL)-21. (A) E-cadherin staining of representative tumour areas of colon
sections on day 42 of chronic dextran sulphate sodium (DSS)-colitis with azoxymethane (AOM)-induced tumour growth. (B) Flow cytometric
determination of CD8CD103, CD8granzyme B and CD8perforin cells in the colon on day 28 of chronic DSS-colitis with AOM-induced tumour growth.
Cells were extracted from the lamina propria on day 28 and stained with fluorochrome-conjugated antibodies. (C) Cytotoxicity of CD8 T cells against
CT-26 cells or E-cadherin+ CT-26 cells. CD8 T cells were isolated from the colon on day 28 of chronic DSS-colitis with AOM-induced tumour growth
and co-cultured with CT-26 cells or E-cadherin+ CT-26 target cells. Cytotoxicity was measured after 24 h of cytolytic activity. (D) TUNEL assay of
representative tumour areas of colon sections on day 42 of chronic DSS-colitis with AOM-induced tumour growth. Data shown are mean values 6
SEM, derived from at least 10 mice per group. Individual points represent one mouse. *p#0.05. (E) Flow cytometric determination of CD8CD103 cells
in the colon of IL-21-deficient mice on day 28 of chronic DSS-colitis with AOM-induced tumour growth after inhibition of interferon (IFN)g. Inhibition of
IFNg was started on day 14. Cells were extracted from the lamina propria on day 28 and stained with fluorochrome-conjugated antibodies.
CTL, cytotoxic T-lymphocyte; HPF, high power field; KO, knock-out; WT, wild-type.
Gut 2011;60:1678e1686. doi:10.1136/gutjnl-2011-300612 1685
Inflammatory bowel disease
group.bmj.com on September 4, 2017 - Published by http://gut.bmj.com/Downloaded from 
functional capacity of cytotoxic CD8 T cells was greatly
increased in the Th1-dominated environment present in IL-
21-deﬁcient mice with intestinal tumour induction.
Owing to the fact that on day 42 of chronic DSS-colitis with
AOM-induced tumour growth in IL-21-deﬁcient mice, the
tumour cell proliferation index is w10%, while the apoptotic
index is about 20%, we consider that these tumours may
undergo regression to some degree on day 42. Our experience
with colitis-associated tumorigenesis models shows that the rate
of tumour cell proliferation is highest at the time when tumours
start to become visible macroscopically and that tumour cell
cytotoxicity becomes apparent slightly later than the ﬁrst
appearance of macroscopic tumour nodules. Therefore this
timing difference is probably the explanation for the differences
seen between the proliferation index and apoptotic index.
In conclusion, we have demonstrated in this study that the
cytokine IL-21 is capable of inﬂuencing the development of chronic
intestinal inﬂammation. Importantly, our results show that IL-
21 is a key cytokine that tips the balance between a tumour-
proliferative and a tumour-suppressive microenvironment,
substantially inﬂuencing tumour growth.
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